Primary Hyperparathyroidism in patients with gastric carcinoid Tumors type-1: an unusual coexistence Abstract #35

Introduction: Although a number of familiar endocrine syndromes are associated with primary hyperparathyroidism (PHP), there is no information regarding its prevalence in other sporadic neuroendocrine diseases.
Aim(s): To investigate the prevalence of PHP in patients with gastric carcinoid type-1 (GC-1) tumors.
Materials and methods: Twenty-six patients with biopsy-proven GC-1 tumors were retrospectively studied. Clinical, biochemical, hormonal, and radiological (including computed tomography (CT) and/or magnetic resonance (MR) imaging of the abdomen, and whole body scintigraphy with 111In-pentetreotide (Octreoscan)) information were recorded. The diagnosis of PHP was based on elevated or high normal serum calcium levels and elevated or inappropriate normal parathyroid hormone (PTH) levels. Further tests for the localization of the hyperfunctioning parathyroid glands included neck ultrasound, 99m-Tc-SESTAMIBI scanning, and cervical or upper mediastenal MR imaging studies. Two age- and gender-matched groups of individuals with (n=49) and without (n=34) thyroid autoimmunity and normal gastric endoscopy were used for comparisons.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dimitrios Thomas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#139 Association of carcinoid with noncarcinoid neoplasms
Introduction: Carcinoid tumors have a complex disease spectrum. Most have a benign clinical course, but some are aggressive, with invasive growth, metastasis and short survival. In carcinoid tumors, more than 20% are associated with noncarcinoid neoplasms. When the second tumor is a more malignant lesion, the prognosis usually is correlated more closely with the noncarcinoid malignant neoplasm.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Joao C Ribeiro
#285 A Case of Primary Hepatic Carcinoid Tumor Misdiagnosed as Hepatocellular Carcinoma (HCC)
Introduction: Carcinoid tumors generally occur in the gastrointestinal and respiratory tracts. Primary carcinoid tumor of the liver is very rare. It may be misdiagnosed as hepatocellular carcinoma, which is very common.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Jila Hazrati
#721 Primary Carcinoid Tumors of the Pancreas
Introduction: Primary pancreatic carcinoids (foregut) are very rare. Diagnosis: high urinary 5-HIAA (or high serum 5-HT) or immunodetection of 5-HT cells.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: professor Claudio Pasquali
#763 Endoscopic Therapy with Argon Plasma Coagulation for Multiple Type 1 Gastric Carcinoid Tumors
Introduction: Data regarding Type I gastric carcinoids and their evolution in prospective series are scarce, thus treatment and follow-up are not codified.
Conference: 10th Annual ENETS Conference (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr. Rodrigo Castano